tetano
Editor, Senior Moderator
Sci Rep
. 2025 Feb 20;15(1):6137.
doi: 10.1038/s41598-025-90766-x. Secondary Hemophagocytic Lymphohistiocytosis in severe COVID-19 - a retrospective cohort study
Julia Oppenauer[SUP] #[/SUP][SUP] 1 [/SUP], Tamara Clodi-Seitz[SUP] #[/SUP][SUP] 2 [/SUP], Andrea Kornfehl[SUP] 1 [/SUP], Christoph Wenisch[SUP] 2 [/SUP], Felix Eibensteiner[SUP] 1 [/SUP], Roman Brock[SUP] 1 [/SUP], Marco Neymayer[SUP] 1 [/SUP], Anita Oppenauer[SUP] 3 [/SUP], Arnold Pilz[SUP] 4 [/SUP], Christoph Veigl[SUP] 1 [/SUP], Daniel Tihanyi[SUP] 5 [/SUP], Robert Strassl[SUP] 6 [/SUP], Hermine Agis[SUP] 7 [/SUP], Sebastian Schnaubelt[SUP] 8 9 [/SUP]
Affiliations
Hemophagocytic lymphohistiocytosis (HLH) is an excessive immune activation with cytokine storm und multi-organ dysfunction. It can occur secondarily, especially due to viral infections like COVID-19. Rapid treatment is crucial for favourable outcomes, but diagnosing HLH is challenging. The most common diagnostic instrument is the H-Score. However, the prognostic value of the H-score has not yet been assessed in detail in the spotlight of secondary HLH in severe COVID-19. COVID-19 patients treated between February 2020 and April 2021 at the intensive care unit (ICU) of the Department of Infectious Diseases and Tropical Medicine, Clinic Favoriten, Vienna, Austria, were included in this study. Data were assessed retrospectively by document review, and the follow-up period was at least 90 days. A total of 208 critically ill COVID-19 patients with an age of 61.8 ± 13.6 years were enrolled in this study. We found an average H-Score in the entire study collective of 94 ± 51 points, and 8.7% had a score ≥ 169 testing positive for HLH. A positive score was associated with increased mortality rates at 28 (66.7 vs. 26.3%, p < 0.001) and 90 days (72.2 vs. 27.9%, p < 0.001). In our cohort study, critically ill COVID-19 patients with an H-Score ≥ 169 during their ICU stay had increased mortality rates at 28 and 90 days. Thus, attention should be paid to individuals with rising or high scores. Therapeutic options and their impact on mortality for patients with COVID-19-associated secondary HLH should be evaluated in further studies.
Keywords: COVID-19; Critical care; H-Score; HLH; Haemophagocytic syndrome; Hemophagocytic lymphohistiocytosis; Intensive care medicine; Intensive care unit; SARS-CoV-2.
. 2025 Feb 20;15(1):6137.
doi: 10.1038/s41598-025-90766-x. Secondary Hemophagocytic Lymphohistiocytosis in severe COVID-19 - a retrospective cohort study
Julia Oppenauer[SUP] #[/SUP][SUP] 1 [/SUP], Tamara Clodi-Seitz[SUP] #[/SUP][SUP] 2 [/SUP], Andrea Kornfehl[SUP] 1 [/SUP], Christoph Wenisch[SUP] 2 [/SUP], Felix Eibensteiner[SUP] 1 [/SUP], Roman Brock[SUP] 1 [/SUP], Marco Neymayer[SUP] 1 [/SUP], Anita Oppenauer[SUP] 3 [/SUP], Arnold Pilz[SUP] 4 [/SUP], Christoph Veigl[SUP] 1 [/SUP], Daniel Tihanyi[SUP] 5 [/SUP], Robert Strassl[SUP] 6 [/SUP], Hermine Agis[SUP] 7 [/SUP], Sebastian Schnaubelt[SUP] 8 9 [/SUP]
Affiliations
- PMID: 39979496
- DOI: 10.1038/s41598-025-90766-x
Hemophagocytic lymphohistiocytosis (HLH) is an excessive immune activation with cytokine storm und multi-organ dysfunction. It can occur secondarily, especially due to viral infections like COVID-19. Rapid treatment is crucial for favourable outcomes, but diagnosing HLH is challenging. The most common diagnostic instrument is the H-Score. However, the prognostic value of the H-score has not yet been assessed in detail in the spotlight of secondary HLH in severe COVID-19. COVID-19 patients treated between February 2020 and April 2021 at the intensive care unit (ICU) of the Department of Infectious Diseases and Tropical Medicine, Clinic Favoriten, Vienna, Austria, were included in this study. Data were assessed retrospectively by document review, and the follow-up period was at least 90 days. A total of 208 critically ill COVID-19 patients with an age of 61.8 ± 13.6 years were enrolled in this study. We found an average H-Score in the entire study collective of 94 ± 51 points, and 8.7% had a score ≥ 169 testing positive for HLH. A positive score was associated with increased mortality rates at 28 (66.7 vs. 26.3%, p < 0.001) and 90 days (72.2 vs. 27.9%, p < 0.001). In our cohort study, critically ill COVID-19 patients with an H-Score ≥ 169 during their ICU stay had increased mortality rates at 28 and 90 days. Thus, attention should be paid to individuals with rising or high scores. Therapeutic options and their impact on mortality for patients with COVID-19-associated secondary HLH should be evaluated in further studies.
Keywords: COVID-19; Critical care; H-Score; HLH; Haemophagocytic syndrome; Hemophagocytic lymphohistiocytosis; Intensive care medicine; Intensive care unit; SARS-CoV-2.